Komponenta komplementa 5

Komponenta komplementa 5
Komponenta komplementa 5
	PDB prikaz baziran na 3cu7.
Dostupne strukture
	3cu7, 1cfa, 1kjs, 1xwe
Identifikatori
Simboli	C5; CPAMD4; MGC142298
Vanjski ID	OMIM: 120900 MGI: 96031 HomoloGene: 20412 GeneCards: C5 Gene
Ontologija gena
Molekularna funkcija	• aktivnost inhibitora endopeptidaze; • vezivanje receptora; • hemokinska aktivnost;
Celularna komponenta	• ekstracelularni region; • kompleks membranskog napada; • ekstracelularni prostor;
Biološki proces	• aktivnost MAPK aktivacije; • hemotaksa; • respons na stres; • inflamatorni respons; • aktivacija komplementa; • aktivacija komplementa, alternativni put; • aktivacija komplement, klasični put; • signalni put G-protein spregnutog receptora; • citoliza;
Pregled RNK izražavanja
	podaci
Ortolozi
Vrsta	Čovek
Entrez	727
Ensembl	ENSG00000106804
UniProt	P01031
RefSeq (mRNA)	NM_001735
RefSeq (protein)	NP_001726
Lokacija (UCSC)	Chr 9:; 122.75 - 122.85 Mb
PubMed pretraga	[1]

Komponenta komplementa 5 je protein koji je kod ljudi kodiran C5 genom.^[1]

Komponenta komplementa 5 je deo sistema komplementa. Ovaj protein se proteolitički razlaže u C5a i C5b^[2]:

C5a ima važnu ulogu u hemotaksi.
C5b formira prvi deo kompleks komplementnog membranskog napada.

Smatra se da C5 nedostatak uzrokuje Leinerovu bolest.

Funkcija

Komponenta komplementa 5 učestvuje inflamatornim i procesima ubijanja ćelija. Ovaj protein se sastoji od alfa i beta polipeptidnih lanaca, koji su povezani disulfidnim mostom. Aktivacioni peptid C5a, koji je anafilatoksin koji manifestuje potentno spazmogeno i hemotaksno dejstvo, je izveden iz alfa polipeptida putem razlaganja konvertazom. C5b peptid može da formira komplekse sa komponentom komplementa C6, i taj kompleks je osnova za formiranje kompleksa membranskog napada.^[1]

Klinički značaj

Mutacije ovog gena uzrokuju deficijenciju komponente komplementa 5, bolest koja čini pacijente sklonim ozbiljnim recidivnim infekcijama. Deficiti ovog gena su bili povezani sa podložnošću cirozi jetre i reumatoidnom artritisu.^[1]

Terapeutske primene

Lek ekulizumab sprečava razlaganje C5 u C5a i C5b.^[3]

Reference

^ ^а ^б ^в „Entrez Gene: complement component 5”.
^ Thomas J. Kindt; Richard A. Goldsby; Barbara Anne Osborne; Janis Kuby (2006). Kuby Immunology (6 изд.). New York: W H Freeman and company. ISBN 1429202114.
^ Dubois E, Cohen A (2009). „Eculizumab”. Br J Clin Pharmacol. 68: 318—319. PMC 2766470 . doi:10.1111/j.1365-2125.2009.03491.x.

Literatura

Dodatna literatura

Tack BF, Morris SC, Prahl JW (1979). „Fifth component of human complement: purification from plasma and polypeptide chain structure.”. Biochemistry. 18 (8): 1490—7. PMID 106884. doi:10.1021/bi00575a016.
Fernandez HN, Hugli TE (1978). „Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.”. J. Biol. Chem.. 253 (19): 6955—64. PMID 690134.
DiScipio RG (1992). „Formation and structure of the C5b-7 complex of the lytic pathway of complement.”. J. Biol. Chem.. 267 (24): 17087—94. PMID 1387399.
Haviland DL; Haviland JC; Fleischer DT; et al. (1991). „Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene.”. J. Immunol.. 146 (1): 362—8. PMID 1984448.
Bohnsack JF; Mollison KW; Buko AM; et al. (1991). „Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.”. Biochem. J.. 273 ( Pt 3): 635—40. PMC 1149811 . PMID 1996961.
Lundwall AB; Wetsel RA; Kristensen T; et al. (1985). „Isolation and sequence analysis of a cDNA clone encoding the fifth complement component.”. J. Biol. Chem.. 260 (4): 2108—12. PMID 2579066.
Zuiderweg ER, Fesik SW (1989). „Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a.”. Biochemistry. 28 (6): 2387—91. PMID 2730871. doi:10.1021/bi00432a008.
Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW (1989). „Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data.”. Biochemistry. 28 (1): 172—85. PMID 2784981. doi:10.1021/bi00427a025.
Haefliger JA, Tschopp J, Vial N, Jenne DE (1989). „Complete primary structure and functional characterization of the sixth component of the human complement system. Identification of the C5b-binding domain in complement C6.”. J. Biol. Chem.. 264 (30): 18041—51. PMID 2808363.
Wetsel RA; Lemons RS; Le Beau MM; et al. (1988). „Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9.”. Biochemistry. 27 (5): 1474—82. PMID 3365401. doi:10.1021/bi00405a012.
Zuiderweg ER, Mollison KW, Henkin J, Carter GW (1988). „Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a.”. Biochemistry. 27 (10): 3568—80. PMID 3408713. doi:10.1021/bi00410a007.
Stewart JL, Kolb WP, Sodetz JM (1987). „Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.”. J. Immunol.. 139 (6): 1960—4. PMID 3624872.
Buhl AM, Osawa S, Johnson GL (1995). „Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor.”. J. Biol. Chem.. 270 (34): 19828—32. PMID 7649993. doi:10.1074/jbc.270.34.19828.
Babkina IN; Seregin SV; Daniliuk NK; et al. (1995). „[Chemico-enzymatic synthesis, cloning and expression of a gene for an analog of human anaphylatoxin C5a]”. Bioorg. Khim.. 21 (5): 359—64. PMID 7661861.
Wang X; Fleischer DT; Whitehead WT; et al. (1995). „Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families.”. J. Immunol.. 154 (10): 5464—71. PMID 7730648.
Oppermann M, Götze O (1995). „Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.”. Immunology. 82 (4): 516—21. PMC 1414921 . PMID 7835913.
Süsal C; Kirschfink M; Kröpelin M; et al. (1994). „Complement activation by recombinant HIV-1 glycoprotein gp120.”. J. Immunol.. 152 (12): 6028—34. PMID 7911492.
Arribas J, Arizti P, Castaño JG (1994). „Antibodies against the C2 COOH-terminal region discriminate the active and latent forms of the multicatalytic proteinase complex.”. J. Biol. Chem.. 269 (17): 12858—64. PMID 8175701.
Süsal C; Kirschfink M; Kröpelin M; et al. (1996). „Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.”. Blood. 87 (6): 2329—36. PMID 8630395.
Ames RS; Li Y; Sarau HM; et al. (1996). „Molecular cloning and characterization of the human anaphylatoxin C3a receptor.”. J. Biol. Chem.. 271 (34): 20231—4. PMID 8702752. doi:10.1074/jbc.271.34.20231.
Fredslund F; Laursen NS; Roversi P; et al. (2008). „Structure of and influence of a tick complement inhibitor on human complement component 5.”. Nat Immunol.. 9 (7): 753—60. PMID 18536718. doi:10.1038/ni.1625.

Spoljašnje veze

Complement+5 на US National Library of Medicine Medical Subject Headings (MeSH)

[entrez-1] а ^б ^в „Entrez Gene: complement component 5”.

[KubyImmunology6th-2] Thomas J. Kindt; Richard A. Goldsby; Barbara Anne Osborne; Janis Kuby (2006). Kuby Immunology (6 изд.). New York: W H Freeman and company. ISBN 1429202114.

[3] Dubois E, Cohen A (2009). „Eculizumab”. Br J Clin Pharmacol. 68: 318—319. PMC 2766470 . doi:10.1111/j.1365-2125.2009.03491.x.

[1]

[2]

[3]